iData Insights

Low Back Pain - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 29, 2016 15:03 IST

Low Back Pain - Pipeline Review, H2 2015 Summary Global Markets Direct s, Low Back Pain - Pipeline Review, H2 2015, provides an overview of the Low Back Pains therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Low Back Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Low Back Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Low Back Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Low Back Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 7

Global Markets Direct Report Coverage 7

Low Back Pain Overview 8

Therapeutics Development 9

Pipeline Products for Low Back Pain - Overview 9

Low Back Pain - Therapeutics under Development by Companies 10

Low Back Pain - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Low Back Pain - Products under Development by Companies 15

Low Back Pain - Companies Involved in Therapeutics Development 16

Adynxx, Inc. 16

Aestus Therapeutics, Inc. 17

Astellas Pharma Inc. 18

Eli Lilly and Company 19

Frontier Biotechnologies Co., Ltd 20

Grunenthal GmbH 21

Hisamitsu Pharmaceutical Co., Inc. 22

Immune Pharmaceuticals Inc. 23

Ipsen S.A. 24

MEDRx Co., Ltd. 25

Mesoblast Limited 26

Nektar Therapeutics 27

Orion Oyj 28

Pacira Pharmaceuticals, Inc. 29

Pfizer Inc. 30

Stayble Therapeutics 31

Low Back Pain - Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Combination Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

(acetaminophen + tramadol hydrochloride) - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

(etodolac + lidocaine) - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

(oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

AB-001 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

abobotulinumtoxin A - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ASP-7962 - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ATX-09002 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

AYX-2 - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

bupivacaine - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

cebranopadol - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

dexmedetomidine hydrochloride - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Drug for Chronic Low Back Pain - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

duloxetine hydrochloride DR - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

HP-3150 - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

lidocaine hydrochloride - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

MPC-06ID - Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

NKTR-181 - Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

tanezumab - Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

zoledronic acid - Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Low Back Pain - Recent Pipeline Updates 74

Low Back Pain - Dormant Projects 87

Low Back Pain - Discontinued Products 88

Low Back Pain - Product Development Milestones 89

Featured News & Press Releases 89

Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 89

Jan 23, 2014: Pfizer Reports Top-Line Results from ALO-02 Phase 3 Study 90

Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity for Cymbalta 90

Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study 90

Appendix 92

Methodology 92

Coverage 92

Secondary Research 92

Primary Research 92

Expert Panel Validation 92

Contact Us 92

Disclaimer 93

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects